View article

Three dimensional (3D) printing was used as a novel medicine formulation technique for production of viable tablets capable of satisfying regulatory tests and matching the release of standard commercial tablets. Hydroxypropyl methylcellulose (HPMC 2208) (Methocel™ K100M Premium) and poly(acrylic acid) (PAA) (Carbopol^® 974P NF) were used as a hydrophilic matrix for a sustained release (SR) layer. Hypromellose^® (HPMC 2910) was used as a binder while microcrystalline cellulose (MCC) (Pharmacel^® 102) and sodium starch glycolate (SSG) (Primojel^®) were used as disintegrants for an immediate release (IR) layer. Commercial guaifenesin bi-layer tablets (GBT) were used as a model drug (Mucinex^®) for this study. There was a favourable comparison of release of the active guaifenesin from the printed hydrophilic matrix compared with the commercially available GBT. The printed formulations were also …